With obesity, the amount of bioavailable IGF-1 increases, possibly via hyperglycemia-induced suppression of IGFBP synthesis and/or hyperinsulinemia-induced promotion of hepatic growth hormone receptor expression and IGF-1 synthesis (10, 11). Here, IGF1 is linked to obesity due to melanocortin 4 receptor deficiency.